ADIG

ADI Global Distribution Inc.

ADIG | NYSE

Price Alert Chart Builder DCF Calculator

$18.39

+$0.91 (+5.21%)

Nov 2, 2026, 12:49 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+5.21%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

21.3

-0.2 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #846/885 (Top 96%)

Full Analysis

Key Statistics

Market Data

Market Cap $1.27B

1D Range

17.60 18.69

52W Range

15.22 28.27

Valuation (TTM)

PE 265.65

PB 0.49

EV/EBITDA 15.50

Valuation (NTM)

Forward PE 8.38

Forward PEG 30.99

Price Target $29.67

Cash Flow

FCF Yield -8.4%

SBC Adj. FCF Yield -8.4%

SBC Impact N/A

Margins

Gross Margin 20.4%

Operating Margin 1.9%

FCF Margin -4.1%

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA 0.1%

ROE 0.2%

ROIC 1.0%

Financial Health

Net Debt

$516M

Current Ratio 2.80

Interest Coverage 1.39

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

ADI Global Distribution, Inc. engages in the distribution of third-party low-voltage products. Its products include security and audio-visual solutions. The company was founded by Maurice Coleman in 1...

Sector Industrials

Industry Industrial - Distribution

Employees 4,119

IPO Date Aug 4, 2026

Website www.adiglobal.com

Fiscal Year n/a

Full Company Profile

Latest News

5 days ago · seekingalpha.com

Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts

Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds into Royal Caribbean Group. Middleby completed the spin-off of Midera Food Processing, announced plans to exit its underperforming business, and continued buying back shares.

7 days ago · seekingalpha.com

Ariel Fund Q3 2026 Leaders And Laggards

ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology customers. Bio-Rad's shares also benefited from the announcement of a broad restructuring program designed to streamline operations and enhance profitability.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$30.00

Upside

+63.13%

Buy (0)

Hold (1)

Sell (0)

Analyst Details ➞